                         SEQUENCE LISTING

<110>  CAMBRIDGE ENTERPRISE LIMITED
 
<120>  ANTIBODY

<130>  N416867WO

<150>  GB 1912008.8
<151>  2019-08-21

<160>  11    

<170>  PatentIn version 3.5

<210>  1
<211>  42
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Ab42

<400>  1

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys 
1               5                   10                  15      


Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile 
            20                  25                  30          


Gly Leu Met Val Gly Gly Val Val Ile Ala 
        35                  40          


<210>  2
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DesAb-O CDR1

<400>  2

Gly Phe Asn Ile Lys Asp Thr 
1               5           


<210>  3
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DesAb-O CDR2

<400>  3

Tyr Pro Thr Asn Gly Tyr 
1               5       


<210>  4
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DesAb-O CDR3

<400>  4

Glu Ser Ala Phe Gly Arg Ala 
1               5           


<210>  5
<211>  124
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  DesAb-O complete sequence

<400>  5

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 
            20                  25                  30          


Tyr Ile Gly Trp Val Arg Arg Ala Pro Gly Lys Gly Glu Glu Trp Val 
        35                  40                  45              


Ala Ser Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Ala Gly Ser Glu Ser Ala Phe Gly Arg Ala Glu Glu Glu Ala Ala 
            100                 105                 110         


Ala Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120                 


<210>  6
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  designed CDR3 sequence

<400>  6

Pro Tyr Gly Ser Met Tyr Val His Ser 
1               5                   


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  designed CDR3 sequence

<400>  7

Pro Met Ser Ala Ile Val Ser 
1               5           


<210>  8
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  designed CDR3 sequence

<400>  8

Gly Ala Val Leu Thr Ala Lys 
1               5           


<210>  9
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  designed CDR3 sequence

<400>  9

Tyr His Ala Asp Ile Ser Asn Glu 
1               5               


<210>  10
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  designed CDR3 sequence

<400>  10

Asp Glu Val Ile Val Arg Ser 
1               5           


<210>  11
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  residues 26-42 of Ab42

<400>  11

Ser Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile 
1               5                   10                  15      


Ala 
    


